Evolving treatment landscapes and advances in scientific and medical innovation increase the pressure on payers, and manufacturers need to be making well-planned and informed decisions about pipeline assets in that context.

We already know that it is never too early to start assessing the value of an asset through the payer lens, but how do we understand and translate any potential opportunities and risks in realizing the value of an asset in a way that can be easily understood by cross-functional stakeholders?

Watch this webinar to understand what payer-relevant challenges and opportunities may present themselves for early pipeline assets and discover ways of making those insights drive more positive market access outcomes.

Discussion points

• Why are increasing pressures in the regulatory and policy arena, coupled with increasingly complex treatment pathways, enhancing the focus on demonstrating value for new assets?
• When payers are under pressure to make decisions based on the assets value, how do you establish and communicate value effectively?
• How can you “right size” your approach to market access by identifying risks and opportunities for an asset early in the clinical development lifecycle?

Learning aims

• Examine how external factors are driving the increasing need to evaluate value potential for your assets in an early pipeline.
• Review examples of how early value assessment can identify critical issues for your asset.
• Understand how a robust value assessment framework enables your teams to align on value risks and opportunities before committing to later-stage clinical development plans.
• Discover why your industry peers are engaging in value assessment across early pipeline assets, and the confidence this brings to successfully inform key development milestones and launch strategy.

Duration: 30 minutes.